Health Canada approves obesity drug Wegovy

Health Canada approves Novo Nordisk’s Wegovy to cut heart attacks
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/90.BMDkfsfZ.js
Novo Nordisk launches obesity drug Wegovy in China
Novo Nordisk said on Monday it has launched its popular obesity drug Wegovy in China, the world's second-largest pharmaceuticals market where it estimates more than 180 million people live with obesity.
Health Canada approves Novo Nordisk's obesity drug to reduce risk of non-fatal heart attack
Canada's health regulator has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or myocardial infarction in some adults
Novo Nordisk's obesity drug Wegovy goes on sale in China
Novo Nordisk's blockbuster weight-loss drug Wegovy is now available for use in China, the company confirmed to AFP on Tuesday, as the Asian nation battles high rates of obesity.A Novo Nordisk spokesperson confirmed to AFP on Tuesday that the drug was "now available in China" for the treatment of adults with obesity and those overweight with at least one weight-related comorbidity.
Canada approves Novo Nordisk's obesity drug to reduce risk of non-fatal heart attack
Canada's health regulator has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or myocardial infarction in some adults, the Danish drugmaker said on Wednesday.
Weight-loss drug approved to reduce risk of non-fatal heart attacks | Canada Tonight
Health Canada has approved the weight-loss drug Wegovy to reduce the risk of non-fatal heart attacks, drug maker Novo Nordisk says. But how does it work? Dr. Samir Gupta discusses Health Canada's decision.
Health Matters: Wegovy approved to reduce heart attack risk
Novo Nordisk says Health Canada has approved its weight loss drug Wegovy to reduce the risk of heart attacks in some adults. Kyle Benning has the details and more in Health Matters for Nov. 27, 2024.
Eli Lilly and Novo Nordisk’s Obesity Moat Just Got Stronger
The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...
Is Novo Nordisk Stock a Buy?
Few companies garner as much reliable attention as Novo Nordisk ( NVO) does these days. With a bull market coinciding with a ...
The Economist2d
Wegovy hits the People’s Republic, at last
But for a long time China’s people struggled to get hold of Wegovy because the country’s regulators had not approved it. Some ...
Novo Nordisk: Supply Strains, Competition, And RFK Concerns Mask Solid Fundamentals
Novo Nordisk faces challenges in weight-loss sector, but acquisition and strong diabetes portfolio position it for future ...
Novo Nordisk’s Wegovy launches in China, offering obesity drug at a fraction of US prices
According to Reuters and CNN, Novo Nordisk announced Monday that it has launched its popular obesity drug Wegovy in China, ...
Bloomberg L.P.5d
Novo Nordisk Foundation Targets US, Europe After Obesity Boost
The Novo Nordisk Foundation’s assets have swelled with the success of diabetes and obesity treatments Ozempic and ...
Novo Nordisk Launches Wegovy Weight-Loss Drug in China
The first prescription for the drug in China will reportedly be issued at a public hospital in Shanghai this week and will ...
Is Novo Nordisk Stock a Buy Right Now?
Novo Nordisk stock has been pretty volatile lately, making it hard to judge whether now is a good opportunity to buy shares.
Novo Nordisk Is Scaling Back Its Hiring Spree in Denmark
Novo Nordisk A/S is cutting back on recruiting in Denmark after reaching the limits of its home country’s labor market in the ...